The Procalcitonin-guided Antibiotics in Respiratory Infections (PARI) project in general practice - a study protocol

Nadia Filipsen, Holger Bro, Lars Bjerrum, Jens-Ulrik Staehr Jensen, Rune Aabenhus, Nadia Filipsen, Holger Bro, Lars Bjerrum, Jens-Ulrik Staehr Jensen, Rune Aabenhus

Abstract

Background: Antibiotic resistance is a global health challenge and the close correlation between antibiotic use and the development of resistance makes it essential to maintain a rational use of antibiotics. Most antibiotics are prescribed in general practice against acute respiratory tract infections (ARTI), even though most of these infections are of viral etiology. Thus, a safe method to substantially reduce unnecessary use of antibiotics in general practice is needed. Procalcitonin (PCT) is a precursor protein with very low circulating levels in the blood under physiological conditions. However, in response serious bacterial infection the level of PCT in the blood may increase significantly. Until recently, quantitative analyses of PCT was performed in hospital laboratories, impeding the implementation of PCT in primary care. Our aim is to determine whether it is possible to lower the use of antibiotics in patients presenting with symptoms of ARTI, without significantly prolonging the period of illness, by using a newly released PCT point-of-care test in general practice.

Methods: The Procalcitonin-Guided Antibiotics in Respiratory Infections (PARI) study is a randomized, single-blinded, non-inferiority, multi-practice intervention study comparing a PCT-group to a control group. Patients (N = 508) will be randomly assigned 1:1 to standard care or to the PCT group. The primary outcomes the duration of illness and symptoms from ARTI measured with the Acute Respiratory Tract Infection Questionnaire. Secondary outcomes include (1) Number of participants in each trial arm exposed to antibiotic treatment at index consultation (day 1) and within 30 days, (2) Number of participants in each trial arm with side effects from antibiotic treatment within 14 days, (3) Number of participants in each trial arm with re-consultations within 30 days, (4) Number of participants in each trial arm admitted to hospital (including diagnosis and mortality) within 30 days, (5) Characterization of biomarker (CRP and PCT) level at index consultation. Tertiary outcomes include patient and general practitioner satisfaction with the use of the PCT point-of-care test, and long-term follow-up.

Discussion: To our knowledge, this is the first study to examine a PCT point-of-care test in general practice with the aim of reducing the use of antibiotics in patients with symptoms of ARTI. Results of this study may prove important in targeting antibiotic treatment only to those patients who need it, thus contributing to limiting the spread of antibiotic resistance.

Trial registration: ClinicalTrials.gov Identifier: NCT04216277 , date of registration: 2. of January 2020.

Keywords: Acute respiratory tract infection; Antibiotic use; General practice; Point-of-care test; Procalcitonin.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow chart of the PARI study
Fig. 2
Fig. 2
Algorithm in case of deviation from the protocol intervention

References

    1. WHO. Antimicrobal resistance. Accessed 25 June 2020. .
    1. Aabenhus R, Siersma V, Hansen MP, Bjerrum L. Antibiotic prescribing in Danish general practice 2004-13. J Antimicrob Chemother. 2016;71(8):2286–94. doi: 10.1093/JAC/DKW117.
    1. Aabenhus R, Hansen MP, Siersma V, Bjerrum L. Clinical indications for antibiotic use in Danish general practice: results from a nationwide electronic prescription database. Scand J Prim Health Care. 2017;35(2):162–9. doi: 10.1080/02813432.2017.1333321.
    1. Garhn-Hansen BMA. Luftvejsinfektioner. Håndbog Om Udredning Og Behandling i Almen Praksis. Audit Projekt Odense. FADLs Forlag. 2005.
    1. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(6):757–62. doi: 10.1086/322627.
    1. Arroll B. Antibiotics for upper respiratory tract infections: an overview of Cochrane reviews. Respir Med. 2005;99(3):255–61. doi: 10.1016/j.rmed.2004.11.004.
    1. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735–43. doi: 10.1086/591126.
    1. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–84. doi: 10.1086/605630.
    1. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol. 2018;9(MAR). doi:10.3389/FIMMU.2018.00302.
    1. Hansen JG, Vestbo J. [Diagnosis and treatment in general practice of lower respiratory tract infections in adults] Ugeskrift for læger. 2002;164(35):4052–5.
    1. Whaley LE, Businger AC, Dempsey PP, Linder JA. Visit complexity, diagnostic uncertainty, and antibiotic prescribing for acute cough in primary care: a retrospective study. BMC Fam Pract. 2013;14:120. doi: 10.1186/1471-2296-14-120.
    1. Bjerrum L, Larsen J, Søndergaard J. [Drug prescription patterns in general practice. Extent, problems and possibilities of improvement] Ugeskrift For Læger. 2002;164(45):5273–7.
    1. Aabenhus R, Jensen JUS, Jørgensen KJ, Hróbjartsson A, Bjerrum L. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2014;(11):CD010130. doi:10.1002/14651858.CD010130.pub2.
    1. Li H, Luo YF, Blackwell TS, Xie CM. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother. 2011;55(12):5900–6. doi: 10.1128/AAC.00335-11.
    1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8. doi: 10.1016/0140-6736(93)90277-n.
    1. Jaworski R, Haponiuk I, Irga-Jaworska N, et al. Monitoring both procalcitonin and C-reactive protein in the early period after tetralogy of Fallot correction in children promotes rational antibiotic use. Adv Med Sci. 2018;63(1):112–8. doi: 10.1016/j.advms.2017.10.003.
    1. Arkader R, Troster EJ, Abellan DM, et al. Procalcitonin and C-reactive protein kinetics in postoperative pediatric cardiac surgical patients. J Cardiothorac Vasc Anesth. 2004;18(2):160–5. doi: 10.1053/j.jvca.2004.01.021.
    1. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000–7. doi: 10.1001/archinte.168.18.2000.
    1. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601–7. doi: 10.1183/09031936.00163309.
    1. Sundheds- og ældreministeriet. National Handlingsplan for Antibiotika Til Mennesker [National Action Plan for Antibiotics to Humans].; 2017. doi:10.1080/01431161.2010.507257.
    1. Ebell MH, Lundgren J, Youngpairoj S. How long does a cough last? Comparing patients’ expectations with data from a systematic review of the literature. Ann Fam Med. 2013;11(1):5–13. doi: 10.1370/AFM.1430.
    1. Thompson M, Vodicka TA, Blair PS, Buckley DI, Heneghan C, Hay AD. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ (Clin Res ed). 2013;347. doi:10.1136/BMJ.F7027.
    1. Mikkel Holmelund; Hans Christian Kjeldsen; Michael Lüscher. Streptokokhalsinfektion, Lægehåndbogen. Lægehåndbogen . Published 2019. .
    1. Dansk Selskab for Almen Medicin. Luftvejsinfektioner - diagnose og behandling (ISBN 978-87-93213-13-5). Published 2014. Accessed 20 Dec 2021. .
    1. Råd for Anvendelse af Dyr Sygehusmedicin (RADS). BEHANDLINGSVEJLEDNING FOR HENSIGTSMÆSSIG ANVENDELSE AF ANTIBIOTIKA I ALMEN PRAKSIS - NEDRE LUFTVEJSINFEKTIONER (vers. 1.0, 2016.11, dok. nr.: 259761). Published 2016. Accessed 20 Dec 2021. .
    1. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9–19. doi: 10.1378/chest.06-1500.
    1. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med. 2018;379(3):236–49. doi: 10.1056/NEJMoa1802670.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner